Top 10 Findings Shaping the Future of Breast Cancer Care From SABCS 2024
SABCS 2024 saw a variety of potentially practice-changing findings on novel antibody drug conjugates, biomarker data, and surgical interventions.
Related Articles
China’s NMPA Grants Breakthrough Therapy Designation to Savolitinib Plus Osimertinib in EGFR+ NSCLC
Savolitinib plus osimertinib received breakthrough therapy designation in China for pretreated, locally advanced or metastatic EGFR-positive NSCLC with MET amplification.
ELCIN: elacestrant in CDK4/6 inhibitor-naïve ER+/HER2- metastatic breast cancer
Virginia Kaklamani, MD, UT Health San Antonio, San Antonio, TX, discusses the rationale and design of the Phase II ELCIN trial (NCT05596409) of elacestrant in…
Focus | Innovative Cancer Care | Elekta
Explore cutting-edge cancer treatment and healthcare innovations in Focus, Elekta’s Online Magazine. Stay informed with the latest articles. Discover more.
Here’s why more Ohioans should be screened for lung cancer
Early diagnoses can significantly improve lung cancer patients’ survival chances, and new screening technologies can help doctors catch cases at more treatable stages.
Balancing cancer care and holiday expectations
Social workers at Fox Chase Cancer Center share tips for managing what everyone hopes for and what’s possible for the patient.
View From the Other Side of the Stethoscope: Simone Biles’… : Oncology Times
An abstract is unavailable.
Findings for Zidesamtinib in Advanced ROS1+ NSCLC and Other Solid Tumors
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL
During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.
Less Common Molecular Alterations in pLGG and Testing Recommendations
The panel examines less prevalent molecular alterations in pediatric low-grade gliomas (pLGG), with a particular focus on BRAF mutations, discussing their characteristics and implications for…
First-in-Class Bicycle Toxin Conjugate Targeting Nectin-4 Generates Excitement in Urothelial Carcinoma
Oncologists detail how zelenectide pevedotin, which is under evaluation in the Duravelo-2 trial, could fill an unmet need in metastatic urothelial carcinoma.